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Abstract
The use of personalized approach for the optimal revascularization strategy in patients 
with ST‐segment elevation myocardial infarction (STEMI) and multivessel coronary 
artery disease (MVCAD) is based on complete revascularization by using latest genera‐
tion drug‐eluting stents, with the choice between multivessel primary stenting and staged 
stenting strategy. The chapter includes theoretical rationale, original single‐center study, 
an original calculator for choosing optimal revascularization strategy, and a clinical case 
example.
Keywords: ST‐segment elevation myocardial infarction, multivessel stenting, 
personalized approach, calculator
1. Introduction
The current guidelines recommend culprit vessel revascularization as a standard treatment 
option in primary percutaneous coronary intervention (PPCI) [1–6]. Nevertheless, patients 
with ST‐segment elevation myocardial infarction (STEMI) and multivessel coronary artery 
disease (MVCAD) constitute up to 50% of all STEMI cases [7, 8]. As known, MVCAD is asso‐
ciated with an adverse short‐ and long‐term outcome after STEMI [9–11]. The definition and 
criteria of MVCAD, timing for nonculprit vessel revascularization, and a number of other tac‐
tical issues are actively discussed in the recent literature [5, 6]. There are three established PCI 
approaches for treatment of MVCAD and STEMI: (1) PPCI of infarct‐related artery (IRA) only 
(culprit vessel revascularization only, CO) with percutaneous coronary intervention (PCI) 
of noninfarct‐related artery based on findings ischemia (spontaneous or during noninvasive 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
stress‐testing); (2) multivessel primary stenting (MPS): IRA is opened with the further dilata‐
tion of other significantly narrowed arteries during the same PPCI procedure; (3) multivessel 
staged stenting (MSS): the IRA only is treated during the first PPCI procedure with subse‐
quent complete revascularization during the second intervention. In this chapter, we justify 
the use of personalized approach for the optimal revascularization strategy in patients with 
STEMI and MVCAD using the latest generation of drug‐eluting stents (DES) with choosing 
MPS or MSS according to our original calculator. The chapter includes theoretical rationale, 
original single‐center study, an original calculator for choosing optimal revascularization 
strategy, and a clinical case example.
2. The evolution of treatment strategies and guidelines for 
revascularization in patients with STEMI and MVCAD. 
The current evidence base. What do we know?
Earlier results of trials comparing MPS and CO approaches were controversial [12–19], prob‐
ably due to the heterogeneity of patient samples, variable endpoints, distinct inclusion criteria 
and different study protocols. European and American Cardiology Societies for 2010–2013 
[1–3] recommended limiting PPCI to the vessel with a culprit stenosis with the exception of 
cardiogenic shock and persistent ischemia after PCI. Moreover, performance of PPCI in a 
noninfarct artery was considered harmful [2].
However, randomized controlled trial (RCT) results [20–23] demonstrated usefulness and 
safety of multivessel stenting in patients with STEMI and MVCAD, both with MPS and MSS 
approaches. The current guidelines were updated by this data [4–6].
MPS approach was tested in two randomized controlled trials: PRAMI (Preventive Angio‐
plasty in Acute Myocardial Infarction) [20] and CvLPRIT (Complete Versus Culprit‐Lesion 
Only Primary PCI) [21]. In PRAMI trial, combined endpoint defined as cardiac death, nonfatal 
recurrent myocardial infarction (MI), or refractory angina at mean follow‐up of 23 months 
occurred in 21 (9%) patients treated with MPS approach compared to 53 (22%) patients 
treated with CO approach (hazard ratio (HR): 0.35; 95% confidence interval (CI): 0.21–0.58) 
[20]. Authors concluded that MPS approach significantly reduces the risk of adverse car‐
diovascular events, as compared to PCI limited to IRA [20]. In the CvLPRIT trial, authors 
showed that major adverse cardiac events (MACE) including all‐cause mortality, recurrent 
MI, heart failure, and ischemic‐driven revascularization at 12 months follow‐up occurred in 
15 (10%) patients treated with MPS approach compared to 31 (21%) patients treated with CO 
approach (HR: 0.45; 95% CI: 0.24–0.84) [21]. In concordance with the PRAMI trial, researchers 
concluded that complete revascularization is beneficial for patients with STEMI and MVCAD 
in comparison with CO approach [21].
The MSS approach was also tested in two randomized controlled trials: DANAMI 3 PRIMULTI 
(Third Danish Study of Optimal Acute Treatment of Patients With ST‐segment Elevation Myocardial 
Infarction) [22] and PRAGUE‐13 (Primary Angioplasty in Patients Transferred From General 
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Community Hospital to Specialized PTCA Units With or Without Emergency Thrombolysis) [23]. 
In the DANAMI 3 PRIMULTI trial, the MSS approach was based on the fractional flow reserve 
(FFR) value ≤ 0.80. Combined endpoint, defined as recurrent MI, all‐cause mortality, and ischemia‐
driven revascularization at 27 months follow‐up occurred in 40 (13%) patients treated with MSS 
approach and in 68 (22%) patients treated with CO approach (HR: 0.56; 95% CI: 0.38–0.83) [22]. 
Therefore, the MSS approach in patients with STEMI and MVCAD reduced the risk of adverse out‐
comes [22]. However, PRAGUE‐13 trial did not find significant differences between MSS and CO 
approaches (frequencies of primary composite endpoint including all‐cause mortality,  recurrent 
MI, or stroke at 38 months follow‐up were 13.9% vs. 16.0%, respectively) [23].
All these findings provided the possibility for endorsement (class IIb) of MPS and MSS strat‐
egies to patients with STEMI and MVCAD by European and American Cardiology Societies 
since 2014 [4] and 2015 [5], respectively. Moreover, in 2016, the American Cardiology 
Society accepted appropriate use criteria for coronary revascularization in patients with 
acute coronary syndrome considering revascularization of arteries with nonculprit stenosis 
at initial procedure or during the initial hospitalization [6]. According to these criteria, (1) 
stable patients immediately following PCI of culprit artery and one or more additional 
severe/intermediate (50–70%) stenoses may be defined as appropriate for MPS approach; 
(2) asymptomatic patients after successful treatment of culprit artery by PPCI and one or 
more additional severe/intermediate (50–70%) stenoses are appropriate for MSS approach 
if having ischemia on noninvasive testing/FFR ≤ 0.80; (3) asymptomatic patients after suc‐
cessful treatment of culprit artery by PPCI and one or more additional severe stenoses may 
be appropriate for MSS approach [6].
Hence, both MPS and MSS approaches have sufficient evidence base for being applied to 
patients with STEMI and MVCAD and are included in recent clinical guidelines. However, 
there is a number of unresolved issues such as stent choice, effect of residual SYNTAX score, 
timing of staged PCI, and the choice between two multivessel stenting approaches. Addressing 
these issues is crucially important for personalized treatment of STEMI and MVCAD.
3. Unresolved issues and prospects for revascularization in STEMI patients
3.1. Multivessel stenting versus staged revascularization with second‐generation drug‐
eluting stents in ST‐elevation myocardial infarction patients: results of randomized trial
3.1.1. Study population
The purpose of this open‐label safety/efficacy randomized clinical trial (NCT01781715) is to 
determine outcomes of 136 consecutive patients with STEMI and multiple coronary artery 
disease (CAD) undergoing multivessel stenting in primary PCI or staged PCI with second‐
generation DES (Resolute Integrity™ Stent, Medtronic). Primary endpoints of this study 
were: (1) all death (cardiac and noncardiac), (2) any MI (STEMI and non‐STEMI), (3) TVR. 
Secondary: (1) composite rate of all death, any MI and TVR, (2) stent thrombosis (ST).
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We examined patients with STEMI and multivessel CAD undergoing primary PCI. Between 
October 2011 and October 2014 in our 24 h catheterization laboratory randomized 136 patients 
with multivessel CAD (defined as ≥70% diameter stenosis of two or more epicardial coronary 
arteries or their major branches by visual estimation with diameter ≥2.5mm). Inclusion  criteria 
were (1) Subject must be at least 18 years of age; (2) Subject is able to verbally confirm under‐
standings of risks and benefits of treatment of either multivessel stenting or staged PCI using 
the zotarolimus‐eluting stent (Resolute Integrity™ Stent, Medtronic) and he or she or his or her 
legally authorized representative provides written informed consent prior to any study‐related 
procedure; (3) Subject must have significant stenoses (≥70%) of two or more than two coronary 
arteries and requiring primary PCI for acute ST elevation myocardial infarction (STEMI) within 
12 h; (4) Target lesions must be located in a native coronary artery with visually estimated 
diameter of less than 2.5 mm and more than 4.0 mm; (5) Target lesion(s) must be amenable for 
percutaneous coronary intervention.
Exclusion criteria were as follows: (1) Single lesions; (2) Acute heart failure Killip III‐IV; (3) ≥50% 
left main stenosis; (4) Small vessels’ diameter (<2.5mm); (5) The patient has a known hypersen‐
sitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel or 
ticagrelor, zotarolimus. Included were patients with the presence of prolonged (more than 30 min) 
chest pain, started less than 12 h before hospital arrival and ST elevation of at least 1 mm in two 
or more contiguous limb electrocardiographic leads or 2 mm in precordial leads.
Procedure success was defined as the achievement of an angiographic residual stenosis of 
less than 20% and a thrombolysis in myocardial infarction (TIMI) flow grade 3 after treat‐
ment of the lesions. Before the procedure patients were treated with loading doses of aspirin, 
clopidogrel or ticagrelor, unfractioned heparin. Post‐PCI medical oral treatment included 
aspirin, statins, and clopidogrel or ticagrelor, which was recommended for 12 months in all 
cases after second‐generation zotarolimus‐eluting stent implantation. Signed informed con‐
sent for primary PCI and for the study was obtained from all patients before the procedure. 
Soon after every diagnostic angiography, the eligible patients were randomly allocated to 
two different strategies: 1. Multivessel stenting in primary PCI (MS primary): the IRA was 
opened followed by dilatation of other significantly narrowed arteries during the same pro‐
cedure. 2. Multivessel stenting in staged revascularization (MS staged): the IRA only was 
treated during the primary intervention while the complete revascularization was planned 
in a second procedure (10.1 ± 5.1 days). The study protocol conforms to the ethical guidelines 
of the 1975 Declaration of Helsinki and was approved by the institution’s human research 
committee.
3.1.2. Definitions and endpoints
Clinical and procedural data were collected by reviewing hospital records and angiographic 
runs stored in DICOM CDs. The primary endpoint of the study was the incidence of major 
adverse cardiac events (MACE) defined as cardiac or noncardiac death, reinfarction, and repeat 
coronary revascularization. For repeat revascularization we included all PCI or CABG occur‐
ring after the baseline procedure and justified by recurrent symptoms, reinfarction, or objective 
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evidence of significant ischemia on provocative testing. In the staged group we classified as 
repeat revascularization only unplanned procedures. Follow‐up was obtained by outpatient 
visits or phone interviews.
We estimated clinical and angiographic criteria of ST. The incidence of ST was assessed through‐
out the follow‐up period, according to the conventional ARC (Academic Research Consortium) 
classification [24]. Clinical criteria consisted of acute onset of chest pain persisting for >15 min 
and/or accompanied by ST‐segment elevation or depression of at least 1 mm in two contigu‐
ous leads in the distribution of the target vessel. All patients with the clinical suspicion of ST 
underwent immediate coronary angiography to confirm the diagnosis  followed by PCI.
Angiographic criteria of stent thrombosis consisted of partial or complete occlusion within 
the previously implanted stent with evidence of fresh thrombus. Within the first 18 h after 
index MI, recurrent MI required recurrent symptoms of myocardial ischemia associated with 
recurrent ST‐segment elevation or depression of at least 1 mm in two contiguous limb electro‐
cardiographic leads or 2 mm in precordial leads lasting at least 30 min. After 18 h, recurrent 
MI was defined as appearance of new Q waves, new left bundle‐branch block, and/or enzyme 
evidence (level of creatine kinase MB fraction and/or troponin) of MI.
3.1.3. Statistical analysis
Continuous variables are presented as mean ± SD, categorical variables as percentages. For 
the endpoint “death” patients were censored at death or December 2015 if alive. For MACE 
patients were censored at the date of first MACE or at the end of follow‐up. Follow‐up was 
100% complete. We used Chi Squared and Mann Whitney “U” test for statistical analysis to 
compare clinical, demographic, angiographic, PCI characteristics, and outcomes in groups. 
All analyses were performed using STATISTICA 8.0 (StatSoft, Tulsa, OK, USA).
3.1.4. Results
3.1.4.1. Baseline characteristics
In general population the mean age was 59 ± 10.6 (31–88) years; 92 (67.2%) were men. The inci‐
dence of diabetes mellitus in study cohort was 22.1%. The MS primary group included 67 
patients, and the MS staged group 69 patients. The elective procedure in the MS staged group 
was performed on average 10.1 ± 5.1 days after the primary PCI. We evaluated the results in 
two study groups (MS primary vs. MS staged).
Table 1 shows the baseline clinical and demographic characteristics in study groups. Patients 
of MS primary and MS staged group were comparable for all clinical and demographic char‐
acteristics. The majority of patients in both groups were male, had hypertension and acute 
heart failure Killip 1.
Table 2 shows the baseline angiographic characteristics and special features of PCI. Mean 
SYNTAX score in the groups did not exceed 19 points, which corresponds to an  intermediate 
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severity of coronary lesions. About half of the patients in each group had 3‐vessel CAD. Total 
mean stent length in each group exceeded 57 mm. There were no statistically significant 
 differences between angiographic characteristics in the groups.
3.1.4.2. Events
Follow‐up was completed in 100% of patients. Over the 12‐month observation, there were no 
significant differences in frequency of adverse cardiovascular events among groups. After a 
follow‐up of 12 months, there was only one noncardiac death in MS staged group (colon can‐
cer). At the same time, fatality outcomes in the groups did not exceed 3% (Table 3). Survival 
free of MI and re‐PCI was 62 (92.5%) patients in MS primary group and 67 (97.1%) in MS 
staged group (p>0.05).
Variables MS primary (n = 67) MS staged (n = 69) Р
n % n %
Three‐vessel disease 32 47.8 31 44.9 0.9
SYNTAX score 19.1 ± 7.9 18.6 ± 7.1 0.9
SYNTAX score ≥23 points 18 26.9 16 23.2 0.8
Contrast medium, ml 325.8 ± 110.2 373 ± 154.5 0.06
Mean number of stents 2.6 ± 0.5 2.7 ± 0.6 0.7
Total mean stent length, mm 57.5 ± 13.4 58 ± 16.2 0.6
Mean stent diameter, mm 3.3 ± 0.4 3.3 ± 0.5 0.3
Table 2. Baseline angiographic characteristics and special features of procedures.
Variables MS primary (n = 67) MS staged (n = 69) Р
n % n %
Age, years 58.6 ± 10.2 59.1 ± 11.1 0.6
Male 48 71.6 43 62.3 0.3
LVEF, % 50.7 ± 9.2 51.8 ± 7.3 0.5
Hypertension 64 94 61 88.4 0.4
Diabetes mellitus 16 23.9 14 20.3 0.8
Peripheral artery disease 13 19.4 20 29 0.3
Previous MI 10 14.9 4 5.8 0.2
Previous stroke 0 0 2 2.9 0.5
Acute heart failure (Killip II) 10 14.9 8 11.6 0.8
Table 1. Patient clinical and demographic characteristics.
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3.1.5. Discussion
The main finding of the present randomized study is that after a follow‐up of 12 months, 
in STEMI patients with multiple coronary lesions treated with multivessel PCI (primary and 
staged (10.1 ± 5.1 days)) with second‐generation DES (Resolute Integrity), revascularization had 
satisfactory outcomes in two different strategies of PCI despite the initial severity of patients, 
including a high frequency of occurrence of diabetes (22.1%) and the average length of the 
stented segment 57.8 ± 14.6 mm.
According to previous guidelines, PCI should be performed only in IRA, at least in patients 
without cardiogenic shock [25]. This recommendation was based on the hypothesis that 
single‐vessel PCI has a more favorable benefit‐to‐risk ratio and better financial implications. 
Some studies suggest that the more conservative strategy of treating only the IRA could avoid 
complications arising from longer procedures, such as the larger use of contrast medium with 
a potentially increased risk of contrast‐induced nephropathy, the increased administration of 
radiation, as well as the danger of ischemia in noninfarcted myocardial regions [15, 18].
There is no randomized data to definitely answer the issues about the specific scientific merits 
of any of the approaches (multivessel stenting in primary PCI or staged PCI) [26]. And there 
is no evidence base for second‐generation DES in STEMI patients with multivessel CAD, but 
in recent years, with the development of new advanced devices the outcome of multivessel 
PCI has markedly improved [17, 19].
Variables MS primary (n = 67) MS staged (n = 69) Р
n % n %
All death 2 3 2 2.9 0.9
of them within 30 days 2 100 1 50 –
Cardiac death 2 3 1 1.4 0.6
MI 5 7.5 2 2.9 0.6
of them within 30 days 1 20 2 100 –
TVR 2 3 1 1.4 0.6
of them within 30 days 0 0 0 0 –
Non‐TVR 0 0 1 1.4 0.9
of them within 30 days 0 0 1 100 –
Combined endpoint (cardiac 
death + MI + TVR)
4 5.9 3 4.3 0.7
Stent thrombosis (on the 
number of patients)
4 5.9 2 2.9 0.7
of them within 30 days 1 25 2 100 –
Table 3. 12‐month outcomes.
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However, the results of recent randomized trials challenged these recommendations 
[1, 4, 27]. The approach to the choice of revascularization strategy in patients with STEMI 
and MVCAD was detailed in 2014 ESC/EACTS Guidelines on myocardial revascular‐
ization [4]. The basic position of the recommendations is that the primary percutaneous 
coronary interven tion (PCI) should be limited to infarct‐related artery (IRA) (excepting car‐
diogenic shock or persistent ischemia, IIa class, level of evidence B) [4]. However, in patients 
with ischemia in noninfarct area primary PCI should be also performed for nonculprit 
lesions up to one week after admission (evidence grade IIa, Level B). Moreover, it is possible 
to carry out revascularization of nonculprit lesions at the time of primary PCI (evidence IIb 
class, level B) [20]. These standards came with the publication of the data from a random‐
ized trial describing the preventive importance of PCI in nonculprit lesions (PRAMI) [1]. 
Nevertheless, the PRAMI trial does not respond to a key question—in which cases do we 
need to perform MS?
To the best of our knowledge the present study is the first that estimates throughout a  follow‐up 
the multivessel stenting during primary PCI and multivessel staged (10.1 ± 5.1 days) PCI with 
second‐generation DES in STEMI patients with multivessel disease. We found that aggressive 
approach (multivessel stenting at the time of primary PCI or staged PCI) in STEMI patients with 
Resolute Integrity stents is associated with low risk of MACE in 12‐month follow‐up period. It 
is clear when compared with the published data. Twelve‐month incidence of MACE in STEMI 
patients with multivessel disease in general cohort (BMS and DES) is 23.9–28%, re‐MI 1.6–8.8%, 
death 3.3–6.3%, ST 1.8–4.3% [12, 15, 18]. In our study, we observed 12‐month MACE, re‐MI, 
death, and ST in 5.1, 5.1, 2.9, and 4.4% of patients, respectively.
Indeed, the inflammatory reaction arising during acute coronary syndromes and responsi‐
ble for plaque instability is not limited to the culprit lesion, but involves the entire coronary 
tree [28]. Our results suggest that the multivessel approach (primary and staged) with second‐
generation DES is safe and possibly less expensive than an incomplete approach by reducing 
the probability of further unplanned procedures. We suppose that multivessel revasculariza‐
tion could decrease the risks and discomfort for patients associated with new unscheduled 
procedures. This hypothesis was also confirmed in the PRAMI trial. In PRAMI trial it was 
shown that in patients with STEMI and multivessel coronary artery disease undergoing infarct 
artery PCI, preventive PCI in noninfarct coronary arteries with major stenoses significantly 
reduced the risk of adverse cardiovascular events, as compared with PCI limited to the infarct 
artery [20].
In two other randomized trials, investigators have specifically assessed the value of preven‐
tive PCI in patients with acute STEMI undergoing PCI in the infarct artery. In one study, 
69 patients were randomly assigned (in a 3:1 ratio) to preventive PCI (52 patients) or no pre‐
ventive PCI (17 patients) [29]. At 1 year, in the preventive‐PCI group, there were nonsignifi‐
cant reductions in the rates of repeat revascularization (17 and 35%, respectively) and cardiac 
death or myocardial infarction (4 and 6%, respectively). In the other trial, 214 patients were 
randomly assigned to one of three groups: no preventive PCI (84 patients), immediate pre‐
ventive PCI (65 patients), and staged preventive PCI performed during a second procedure 
about 40 days later (65 patients) [17]. At 2.5 years, the rate of repeat revascularization was 
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less frequent in the immediate—and staged—preventive‐PCI groups combined, as compared 
with the group receiving no preventive PCI (11 and 33%, respectively), and there was a non‐
significant decrease in the rate of cardiac death (5 and 12%, respectively). The results of these 
studies are consistent with those of our study.
3.1.6. Conclusions
There is no doubt about the fact that the results of revascularization in STEMI patients with 
multivessel CAD may be improved by using the latest generation of DES (Resolute Integrity™ 
Stent, Medtronic). It is clear that further research in this area should be directed to the search 
criteria according to which it would be possible to choose a strategy of revascularization 
for PCI differentiated. Also important is to have an objective angiographic criteria indicat‐
ing  sufficient volume of revascularization performed in the hospital period with primary or 
staged multivessel stenting. In this context, in the next section of this chapter will be pre‐
sented the relevant data of our own study—prognostic role of initial and residual SYNTAX 
score in STEMI patients after primary PCI.
4. Prognostic role of initial and residual SYNTAX score in patients with 
ST‐segment elevation myocardial infarction after primary percutaneous 
coronary intervention
4.1. Methods
We recruited 327 consecutive patients and carried out a single‐center registry study. 
The study was performed in accordance with the principles of Good Clinical Practice 
and the Declaration of Helsinki. The local ethical committee approved the study and all 
the participants provided written informed consent after receiving a full explanation of 
the study. Criteria of inclusion were (1) hospital admission within 12 h of STEMI onset 
requiring the performance of primary PCI; (2) MVCAD defined as hemodynamically 
significant (≥70%) stenosis of two or more coronary arteries; (3) technical ability to per‐
form PCI. Criteria of exclusion were (1) acute heart failure Killip class III‐IV (pulmonary 
edema and cardiogenic shock); (2) left main coronary artery stenosis ≥50%. Before PCI, 
all patients received a loading dose of acetylsalicylic acid (250–500 mg) and clopidogrel 
(600 mg). Successful PCI was defined as the reduction of stenosis to <20% and a TIMI flow 
grade 3. After the PCI, all the patients received aspirin, statins, and clopidogrel during 1 
year of follow‐up.
We first evaluated the prognostic value of initial SYNTAX score that was calculated before 
PCI. Patients were divided into two groups depending on the severity of coronary lesions: 
SYNTAX ≤ 22 points (n = 213) and SYNTAX ≥ 23 points (n = 114). We then evaluated resid‐
ual SYNTAX score that was calculated after PCI. Likewise, patients were stratified into two 
groups: SYNTAX ≤ 8 points (n = 243) and SYNTAX ≥ 9 points (n = 74). The SYNTAX score was 
assessed using a calculator (http://www.rnoik.ru/files/syntax/index.html).
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Variables Patients (n = 327) Р value
Initial SYNTAX ≤ 22 (n = 213) Initial SYNTAX ≥ 23 (n = 114)
n % n %
Age, years 59.1 ± 9.9 60.9 ± 10.6 0.08
Male gender 142 66.6 74 64.9 0.8
LVEF, % 52.5 ± 7.2 48.4 ± 8.8 0.000009
Arterial hypertension 188 88.3 103 90.3 0.7
Diabetes mellitus 47 22 20 17.5 0.4
Peripheral artery disease 56 26.3 33 28.9 0.7
Past medical history of MI 21 9.8 29 25.4 0.0001
Past medical history of stroke 8 3.7 3 2.6 0.8
Acute heart failure (Killip class II) 17 7.9 21 18.4 0.009
Table 4. Patient clinical and demographic features (initial SYNTAX score groups).
4.2. Results
4.2.1. Baseline characteristics
Table 4 demonstrates the baseline clinical and demographic characteristics in study groups. 
As shown, patients with severe coronary atherosclerosis (SYNTAX ≥ 23) were characterized by 
(1) older age; (2) decreased left ventricular ejection fraction (LVEF); (3) more frequent past med‐
ical history of MI; (4) more severe acute heart failure compared to those with SYNTAX ≤ 22.
Table 5 shows a comparison of clinical and demographic characteristics of patients after pri‐
mary PCI. Patients with SYNTAX ≥ 9 were characterized by (1) older age; (2) higher prevalence 
of females; (3) decreased LVEF; (4) more frequent past medical history of MI and peripheral 
artery disease compared to those with SYNTAX ≤ 8.
Variables Patients (n = 317) Р value
Residual SYNTAX ≤ 8 (n = 243) Residual SYNTAX ≥ 9 (n = 74)
n % n %
Age, years 58.8 ± 9.9 63.1 ± 10.6 0.001
Male 76 31.3 34 55.9 0.03
LVEF, % 51.4 ± 7.6 49.2 ± 9.2 0.08
Hypertension 218 89.7 68 91.9 0.7
Diabetes mellitus 45 18.5 20 27 0.2
Peripheral artery disease 59 24.3 28 37.8 0.03
Previous MI 31 12.8 17 23 0.05
Acute heart failure (Killip II) 29 11.9 10 13.5 0.9
Table 5. Patient clinical and demographic features (residual SYNTAX score groups).
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Analysis of the angiographic parameters and features of revascularization revealed a direct 
relationship between the initial SYNTAX ≥ 23 and residual SYNTAX ≥ 9 (Table 3). In com‐
parison with residual SYNTAX ≤ 8 patients, those with SYNTAX ≥ 9 patients had (1) a higher 
prevalence of initial SYNTAX ≥ 23; (2) more frequent three‐vessel disease; (3) more rare use of 
multivessel stenting strategy; (4) less percentage of successful PCI in IRA (Table 6).
4.2.2. Events
Within 1 year of follow‐up, five deaths were reported in initial SYNTAX ≤ 22 group (Table 7). 
Four of them were due to MACE; the fifth was from cancer. Cases of cardiac death were 
due to (1) rupture of the myocardium on the second day after unsuccessful PCI of IRA; (2) 
stent thrombosis; (3) sudden cardiac arrest. We also observed seven nonfatal MI (Table 4). 
Three of them developed as a result of stent thrombosis, two as a result of destabilized non‐
culprit lesions, one as a complication of elective PCI, and one occurred 2 months after the 
Variables Residual SYNTAX ≤ 8 (n = 243) Residual SYNTAX ≥ 9 (n = 74) Р value
n % n %
Three‐vessel disease 119 49 62 83.8 0.0001
Initial SYNTAX score 18.9 ± 7.7 26.8 ± 7.7 0.0000001
Procedure success 235 96.7 66 89.2 0.02
Multivessel stenting 80 32.9 7 9.5 0.0001
Staged PCI 163 67.1 67 90.5 0.0001
Mean time between 
PCI, days
80.1 ± 49.5 80.1 ± 46.4 0.9
Table 6. Baseline lesions and angiographic characteristics (residual SYNTAX score groups).
Variables Initial SYNTAX ≤ 22 (n = 213) Initial SYNTAX ≥ 23 (n = 114) Р value
n % n %
Death from all causes 5 2.3 12 10.5 0.004
Cardiovascular death 4 1.9 11 9.6 0.003
Myocardial infarction 7 3.3 12 10.5 0.02
Repeated target vessel 
revascularization
10 4.7 9 7.9 0.4
Repeated nontarget vessel 
revascularization
2 0.9 2 1.8 0.9
Stent thrombosis 4 1.9 10 8.8 0.008
Combined endpoint* 10 4.7 12 10.5 0.008
*All death + MI + TVR.
Table 7. Outcomes after 1 year of follow‐up (initial SYNTAX score groups).
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index event. Six out of ten cases of repeated target vessel revascularization were caused by 
the development of in‐stent restenosis (Table 4). Four other cases were associated with stent 
thrombosis. Twelve deaths were reported in patients with initial SYNTAX ≥ 23; eleven of them 
were caused by MACE while the twelfth was due to stroke (Table 4). Out of these, eleven 
deaths, five were the result of stent thrombosis, three were the result of an unsuccessful PCI 
and progressive acute heart failure, two patients died due to myocardial rupture, and the last 
case was associated with air embolism of the right coronary artery. Only one case of repeated 
target vessel revascularization out of nine was the result of in‐stent restenosis, while the other 
eight were performed in patients with stent thrombosis (Table 7).
Initial SYNTAX score ≥ 23 was significantly associated with a higher risk of death from any 
cause, cardiac death, recurrent MI, stent thrombosis, and combined endpoint (Table 8).
There was a significantly higher frequency of death from any cause, recurrent MI, and 
repeated nontarget vessel revascularization among patients with residual SYNTAX ≥ 9 com‐
pared to those with residual SYNTAX ≤ 8 (Table 9).
Residual SYNTAX ≥ 9 successfully predicted MACE such as death, recurrent MI, and repeated 
nontarget vessel revascularization (Table 10).
Major adverse cardiovascular outcomes OR (95% CI)
Death from any cause 4.9
Cardiac death 5.6
Recurrent myocardial infarction 3.5
Stent thrombosis 5.0
Combined endpoint 2.4
Table 8. Prognostic factors of MACE based on the initial SYNTAX score.
Variables Residual SYNTAX ≤ 8 
(n = 243)
Residual SYNTAX 
≥ 9 (n = 74)
Р value
n % n %
Death 7 2.9 10 13.5 0.001
Myocardial infarction 10 4.1 8 10.8 0.05
Repeated target vessel 
revascularization
11 4.5 9 12.2 >0.05
Repeated nontarget vessel 
revascularization
6 2.5 7 9.5 0.02
Stent thrombosis 5 2.1 5 6.8 >0.05
Table 9. Outcomes after 1 year of follow‐up (residual SYNTAX score groups).
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4.3. Discussion
The main objective of this study was to determine the value of initial and residual SYNTAX 
score for prediction of adverse revascularization outcomes in patients with STEMI and 
MVCAD. To the best of our knowledge, there is little evidence demonstrating the prognostic 
value of initial and residual SYNTAX score in STEMI patients who underwent primary PCI. 
Meanwhile, there is a need for objective criteria including the severity of coronary lesions, 
which could optimize the choice of revascularization strategy for these patients [30, 31].
Here we showed that initial SYNTAX ≥ 23 points can predict the development of MACE 
within 1 year of follow‐up. Patients with SYNTAX ≥ 23 had significantly higher incidence of 
adverse outcomes such as death, MI, and stent thrombosis. However, residual SYNTAX score 
can be even more informative since it reflects the completeness of myocardial revasculariza‐
tion and risk of adverse events in the short‐ and long‐term follow‐up. Residual SYNTAX score 
≥ 9 was significantly associated with an increased risk of death, recurrent MI, and repeated 
nontarget vessel revascularization. High residual SYNTAX score was more prevalent in 
groups with a predominance of female patients, three‐vessel coronary disease, peripheral 
atherosclerosis, past medical history of MI, and reduced LVEF. It is known that these clini‐
cal and demographic indicators themselves have an adverse effect on long‐term prognosis 
after MI [30, 31]. However, it cannot be excluded that adverse cardiovascular events are 
more dependent on revascularization completeness in the hospital period and, therefore, on 
residual SYNTAX score at the time of discharge from the hospital. It is important to note the 
direct association of the initial SYNTAX score ≥ 23 with residual SYNTAX score ≥ 9 points. 
We suggest that patients with initial severe coronary atherosclerosis are likely to retain a high 
residual SYNTAX at the end of hospitalization.
This highlights the need for complete revascularization in the early stages, including MS strat‐
egy (simultaneous and staged a tightly limited time interval between PCI), as well as a com‐
bination of primary PCI with subsequent coronary bypass surgery. Moreover, patients with 
high residual SYNTAX score may need more efficient schemes of anticoagulant and antiplate‐
let therapy with the use of modern drugs (bivalirudin, ticagrelor, prasugrel). Considering the 
desirability of multivessel PCI strategy targeting not only IRA but also nonculprit lesions in a 
limited time interval [4], we assume that the target value of residual SYNTAX score in STEMI 
patients to the end of in‐hospital period is ≤ 8 points. This algorithm is particularly reasoning 
given a sufficiently high proportion of unsuccessful PCI in patients with severe initial and 
residual SYNTAX (10.8%).
Major adverse cardiovascular outcomes OR (95% CI)
Death 3.4 (1.5–7.9)
Recurrent myocardial infarction 2.7 (1.2–6.1)
Repeated nontarget vessel revascularization 2.6 (1.2–5.5)
Table 10. Prognostic factors of MACE based on the residual SYNTAX score.




Both initial and residual SYNTAX score can predict death from all causes and/or MACE in 
patients with STEMI and MVCAD. Patients with high initial SYNTAX score tend to have a high 
residual SYNTAX score. Therefore, the patients with high initial SYNTAX score require com‐
plete revascularization and efficient antiplatelet therapy. Probably, it is required to develop a 
model of differentiated selection of the optimal revascularization strategy for STEMI patients 
to reduce the residual SYNTAX score to the end of in‐hospital period to ≤ 8 points using pri‐
mary multivessel stenting or staged PCIs. These results may be useful for risk stratification in 
patients with STEMI and MVCAD. In this context, in the next section of this chapter will be 
presented the relevant data of our own study—personalized choice of optimal strategy revas‐
cularization in STEMI patients with MVCAD.
5. Personalized choice of optimal revascularization strategy in patients 
with STEMI and MVCAD
5.1. Methods and statistical analysis
Having recruited 327 consecutive patients, we carried out a single‐center registry study. Criteria 
of inclusion were (1) hospital admission within 12 h of STEMI onset requiring the performance 
of PPCI; (2) MVCAD defined as hemodynamically significant (≥70%) stenosis of ≥ 2 coronary 
arteries; (3) technical ability to perform PPCI. Criteria of exclusion were (1) acute heart fail‐
ure Killip class III‐IV, i.e., pulmonary edema and cardiogenic shock; (2) left main coronary 
artery stenosis ≥ 50%. Before PPCI, all patients received a loading dose of acetylsalicylic acid 
(250–500 mg) and clopidogrel (600 mg). Successful PPCI was defined as the reduction of ste‐
nosis to < 20% and a TIMI flow grade 3. After the PCI, all the patients received aspirin, statins, 
and clopidogrel during 1 year of follow‐up. Patients were divided into two groups: treated 
with MPS approach (n = 91) and treated with MSS approach (n = 236). The second stage of 
PCI in those who were treated with MSS approach was carried out 3–6 months after PPCI. 
After 12 months of follow‐up, both cardiac and noncardiac death, recurrent MI, and repeat 
coronary revascularization were defined as primary endpoints. Repeated revascularization was 
performed utilizing PCI after the baseline procedure due to the recurrent symptoms, recurrent 
MI, or significant ischemia at provocative testing. In patients treated with MSS approach, we 
defined only unplanned procedures as repeated revascularization. Follow‐up was conducted 
by outpatient visits or phone interviews.
We collected the data on age, gender, acute heart failure (Killip class), left ventricular ejection 
fraction, SYNTAX score, peripheral atherosclerosis (PA), past medical history of myocardial 
infarction or stroke, arterial hypertension, diabetes mellitus, MVCAD, and use of drug‐eluting 
stents.
Risk stratification models were obtained using stepwise logistic regression with the calculation 
of ROC curve and area under the curve (Figures 1 and 2).
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Patient groups did not have any significant differences in clinical or demographic character‐
istics (Table 11) as well as in angiographic features (Table 12) and characteristics of vascular 
access or implanted stents (Table 13).
Strikingly, there were no significant differences in outcomes between two revascularization 
strategies (Table 14).
Prognostic coefficients for each group of patients are presented in Table 15.
The values of prognostic coefficients were directly related to the risk of adverse outcome (Table 15). 
Past medical history of MI, severe coronary atherosclerosis (SYNTAX score ≥ 23), elderly age, and 
Figure 2. ROC curve of the model calculated for MSS strategy.
Figure 1. ROC curve of the model calculated for MPS strategy.
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female gender showed significant predictive ability of an adverse outcome for patients treated 
with MPS, while past medical history of MI or stroke, PA, arterial hypertension, three‐vessel dis‐
ease, and the use of non‐DES were the predictors of an adverse outcome in those treated using 
MSS approach. The following clinical case represents an example of utilizing interactive calculator 
for the selection of the optimal revascularization strategy in a patient with STEMI and MVCAD.
5.3. Clinical case: using a calculator for a personalized selection of the optimal 
revascularization strategy in a patient with STEMI and MVCAD
Female, 64 years old, was admitted to the hospital with STEMI. The time from onset of symp‐
toms to hospital admission was 4 h. The patient had a number of cardiovascular risk  factors: 
diabetes, hypertension, PA (two‐sided stenosis of internal carotid arteries), and residual 
effects of stroke. ECG showed signs of ST‐segment elevation in leads V1–V5 > 2 mm. Ejection 
fraction on echocardiography was 33%.
Variables MPS (n = 91) MSS (n = 236) Р
n % n %
Age, years 59.2 ± 10.2 60.1 ± 10.2 0.6
Male gender 62 68.1 154 65.3 0.6
LVEF, % 51.1 ± 8.8 50.7 ± 7.8 0.97
Arterial hypertension 79 86.8 208 88.1 0.9
Diabetes mellitus 17 18.7 49 20.8 0.8
Peripheral artery disease 20 21.9 68 28.8 0.4
Past medical history of MI 9 9.9 40 16.9 0.3
Past medical history of stroke 0 12 5.1 0.5
Acute heart failure (Killip class II) 11 12.1 28 11.9 0.8
LVEF—left ventricular ejection fraction; MI—myocardial infarction.
Table 11. Patient clinical and demographic features.
Variables MPS (n = 91) MSS (n = 236) Р
n % n %
Three‐vessel 
disease
50 54.9 132 55.9 0.9
SYNTAX score 18.9 ± 7.5 21.5 ± 8.6 0.1
LAD‐IRA 36 39.5 86 36.4 0.8
Cx‐IRA 17 18.7 53 22.5 0.8
RCA‐IRA 38 41.7 97 41.1 0.9
IRA—infarct‐related artery; LAD—left anterior descending artery; Cx—circumflex artery; RCA—right coronary artery.
Table 12. Baseline angiographic characteristics.
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According to angiography data, multiple coronary disease occurred: subtotal lesion of the prox‐
imal and distal segment of right coronary artery (RCA), thrombotic occlusion of the proximal 
segment of left anterior descending (LAD) artery with blood flow TIMI 0, subtotal bifurcation 
stenosis of circumflex (Cx) artery (Figure 3).
Variables MPS (n = 91) MSS (n = 236) Р
n % n % n
Death from all causes 3 3.3 14 5.9 0.5
Cardiac death 3 3.3 12 5.1 0.7
MI 3 3.3 16 6.8 0.3
Target vessel revascularization 4 4.4 13 5.5 0.9
Nontarget vessel revascularization 0 0 4 1.7 0.5
Combined endpoint* 7 7.7 24 10.2 0.6
Stent thrombosis 3 3.3 11 4.7 0.8
*Combined endpoint—death, MI and unplanned revascularization (TVR and non‐TVR).
Table 14. Outcomes after 1 year of follow‐up.
Variables MPS (n = 91) MSS (n = 236) Р
n % n n
Femoral access 43\91 47.3 255\472 54.6 0.5
Radial access 46\91 50.5 212\472 45.4 0.6
Shoulder access 2\91 2.2 5\472 1 0.7
Successful PCI 84\91 92.3 444\472 94.1 0.9
Contrast medium, ml 328.2 ± 120.7 364.1 ± 165.5 0.07
The average number of stents 
implanted in IRA
1.3 ± 0,5 1.4 ± 0,6 0.7
DES in IRA 48 52.7 125 52.9 0.9
The average number of stents 
implanted in non‐IRA
1.2 ± 0.5 1.4 ± 0.7 0.7
DES in non‐IRA 41 45 116 49.2 0.7
The average length of IRA stented 
segment, mm
28.9 ± 12.6 29.3 ± 13.7 0.8
The average length of non‐IRA 
stented segment, mm
24.2 ± 11.7 28.1 ± 15.4 0.5
The average diameter of IRA stent, 
mm
3.3 ± 0.4 3.4 ± 0.5 0.8
The average diameter of non‐IRA 
stent, mm
3.2 ± 0.5 3.2 ± 0.4 0.9
Table 13. Characteristics of vascular access and implanted stents in patient groups.
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Using our original calculator, we counted the probability of an adverse outcome for MPS and 
MSS strategies (Figure 4). As seen from Figure 4, MPS strategy was selected as favorable, 
while MSS strategy showed a poor prognosis for the patient.
Hence, the patient underwent multivessel stenting of LAD, Cx and RCA (five DES implanted 
in total) (Figure 5).
The patient’s conditions were satisfactory. On the 14th day, the patient was discharged from 
the hospital. There was no angina but patient experienced chronic heart failure II‐III functional 
Risk factor Presence of risk factor Prognostic coefficients for 
MPS
Prognostic coefficients for 
MSS
Elderly age No 0.031 0.132
Yes 0.192 0.195
Female No 0.048 0.169
Yes 0.138 0.134




Peripheral atherosclerosis No 0.071 0.132
Yes 0.1 0.203
Past medical history of MI No 0.049 0.1353
Yes 0.3 0.25
Arterial hypertension No 0.125 0.043
Yes 0.072 0.165
Diabetes mellitus No 0.068 0.15
Yes 0.111 0.163




Three‐vessel disease No 0.064 0.097
Yes 0.091 0.189
SYNTAX score ≥23 No 0.045 0.150
Yes 0.16 0.156
LVEF (3) ≤40% 0.111 0.077
(2) 41–49% 0.148 0.224
(1) ≥50% 0.036 0.128
DES No 0.075 0.182
Yes 0.078 0.041
MI—myocardial infarction; LVEF—left ventricular ejection fraction; DES—drug‐eluting stents.
Table 15. Prognostic factors of unfavorable outcome depending on the revascularization strategy.
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class (NYHA classification). Current diabetes and arterial hypertension were adequately 
controlled with proper medications. After 2 years, the patient underwent repeated coronary 
angiography. There were no stenoses of coronary arteries (Figure 6). According to echocar‐
diography, LVEF was 45%, with a remained anterior wall hypokinesis.
Therefore, we successfully selected an optimal revascularization strategy. This restored the 
function of anterior myocardial wall, prevented destabilization of Cx and RCA stenosis, and 
provided a satisfactory quality of life.
5.4. Conclusions
Here we defined the risk factors of an adverse outcome and designed a calculator for the 
personalized choice of the optimal revascularization strategy for patients with STEMI and 
MVCAD.
Figure 3. Angiography of the patient with STEMI and multiple coronary disease. A: Subtotal lesion of the proximal and 
distal segment of right coronary artery; B: Thrombotic occlusion of the proximal segment of left anterior descending 
artery and subtotal bifurcation stenosis of circumflex artery.
Figure 4. Using the model to calculate the probability of unfavorable prognosis for MPS (A) and MSS strategies (B); 
1—presence of factor; 0—absence of factor; 3—LVEF ≤ 40%; PA—peripheral atherosclerosis; MI—myocardial infarction; 
AH—arterial hypertension; EF—ejection fraction; DES—drug‐eluting stents.




Around 50% of patients with STEMI have MVCAD that significantly worsens prognosis. 
There are three treatment approaches to these patients: culprit vessel intervention only, 
with ischemia‐based PCI of non‐IRA, MV stenting either at the time of PPCI or as a planned, 
staged procedure. Both MPS and MSS have evidence base and are approved by the current 
clinical guidelines. Treatment of culprit vessel only leads to worse outcomes. Complete 
revascularization, achievable through either MPS or MSS, is the key aim that was confirmed 
by our single‐center registry study of initial and residual SYNTAX score. However, the 
choice between MPS and MSS is a crucially important issue. Here we defined the risk factors 
of adverse outcomes after either of these strategies and developed an original calculator for 
the choice of an optimal stenting strategy. Moreover, we carried out a randomized clinical 
trial and revealed that results of revascularization in patients with STEMI and MVCAD may 
be improved by using the latest generation DES such as Resolute Integrity™ Stent.
Figure 5. Angiography of the patient with STEMI after stenting. A—LAD and Cx; B—RCA.
Figure 6. Angiography of the patient with STEMI 24 months after stenting A—RCA; B—LAD and Cx.
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Hence, we justify the use of personalized approach for the optimal revascularization strategy 
in patients with STEMI and MVCAD using the latest generation of DES with choosing MPS 
or MSS according to our original calculator.
Author details
Vladimir I. Ganyukov1* and Roman S. Tarasov2
*Address all correspondence to: ganyukov@mail.ru
1 Laboratory of Interventional Cardiology, State Research Institute for Complex Issue of 
Cardiovascular Diseases, Kemerovo, Russia
2 Laboratory of Reconstructive Surgery, State Research Institute for Complex Issue of 
Cardiovascular Diseases, Kemerovo, Russia
References
[1] Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: the 
task force on myocardial revascularization of the European Society of Cardiology 
(ESC) and the European Association for Cardio‐Thoracic Surgery (EACTS). Eur Heart 
J. 2010;31(20):2501‐2555.
[2] O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the man‐
agement of ST‐elevation myocardial infarction: executive summary: a report of the 
American College of Cardiology Foundation/American Heart Association Task Force on 
Practice Guidelines. Circulation. 2013;127:529‐555.
[3] Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myo‐
cardial infarction in patients presenting with ST‐segment elevation. Eur Heart J. 
2012;33:2569‐2619.
[4] Windecker S, Kolh P, Alfonso F, et al. for the Task Force on Myocardial Revascularization 
of the European Society of Cardiology (ESC) and the European Association for Cardio‐
Thoracic Surgery (EACTS). 2014 ESC/EACTS guidelines on myocardial revasculariza‐
tion. Eur Heart J. 2014;35:2541‐2619.
[5] Levine GN, O'Gara PT, Bates ER, et al. 2015 ACC/AHA/SCAI focused update on primary 
percutaneous coronary intervention for patients with ST‐elevation myocardial infarc‐
tion: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary 
Intervention and the 2013 ACCF/AHA Guideline for the Management of ST‐Elevation 
Myocardial Infarction: a report of the American College of Cardiology/American Heart 
Association Task Force on clinical practice guidelines and the society for cardiovascular 
angiography and interventions. J Am Coll Cardiol. 2016;67:1235‐1250.
Current Concept of Revascularization in STEMI Patients with Multivessel Coronary Artery Disease...
http://dx.doi.org/10.5772/67884
37
[6] Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 
2016 appropriate use criteria for coronary revascularization in patients with acute coro‐
nary syndromes. http://dx.doi.org/10.1016/j.jacc.2016.10.034
[7] Cardarelli F, Bellasi A, Ou FS, et al. Combined impact of age and estimated glomeru‐
lar filtration rate on in‐hospital mortality after percutaneous coronary intervention 
for acute myocardial infarction (from the American College of Cardiology National 
Cardiovascular Data Registry). Am J Cardiol 2009;103:766‐771.
[8] Park DW, Clare RM, Schulte PJ, et al. Extent, location, and clinical significance of non‐
infarct related coronary artery disease among patients with ST‐elevation myocardial 
infarction. JAMA 2014;312:2019‐2027.
[9] Parodi G, Mernisha G, Valenti R, et al. Five year outcome after primary coronary inter‐
vention for acute ST elevation myocardial infarction: results from a single centre experi‐
ence. Heart. 2005;91:1541‐1544.
[10] Muller DW, Topol EJ, Ellis SG, et al. Thrombolysis and angioplasty in myocardial infarc‐
tion (TAMI) study group. Multivessel coronary artery disease: a key predictor of short‐
term prognosis after reperfusion therapy for acute myocardial infarction. Am Heart J. 
1991;121:1042‐1049.
[11] Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success 
and clinical outcomes in patients undergoing primary percutaneous coronary interven‐
tion for acute myocardial infarction. Eur Heart J. 2007;28:1709‐1716.
[12] Hannan EL, Samadashvili Z, Walford G, et al. Culprit vessel percutaneous coronary 
intervention versus multivessel and staged percutaneous coronary intervention for ST‐
segment elevation myocardial infarction patients with multivessel disease. J Am Coll 
Cardiol Intervent. 2010;3:22‐31.
[13] Toma M, Buller CE, Westerhout CM, et al. Nonculprit coronary artery percutaneous cor‐
onary intervention during acute ST‐segment elevation myocardial infarction: insights 
from the APEX‐AMI trial. Eur Heart J. 2010;31:1701‐1707.
[14] Cavender MA, Milford‐Beland S, Roe MT, et al. Prevalence, predictors, and in‐hos‐
pital outcomes of non‐infarct artery intervention during primary percutaneous coro‐
nary intervention for ST‐segment elevation myocardial infarction (from the National 
Cardiovascular Data Registry). Am J Cardiol. 2009;104:507‐513.
[15] Corpus RA, House JA, Marso SP, et al. Multivessel percutaneous coronary interven‐
tion in patients with multivessel disease and acute myocardial infarction. Am Heart J. 
2004;148:493‐500.
[16] Kornowski R, Mehran R, Dangas G, et al. Prognostic impact of staged versus “one‐time” 
multivessel percutaneous intervention in acute myocardial infarction: analysis from the 
HORIZONS‐AMI (harmonizing outcomes with revascularization and stents in acute 
myocardial infarction) trial. J Am Coll Cardiol. 2011;58: 704‐711.
Interventional Cardiology38
[17] Politi L, Sgura F, Rossi R, et al. A randomised trial of target‐vessel versus multi‐vessel 
revascularization in ST‐elevation myocardial infarction: major adverse cardiac events 
during long‐term follow‐up. Heart. 2010;96:662‐667.
[18] Roe MT, Cura FA, Joski PS, et al. Initial experience with multivessel percutaneous coro‐
nary intervention during mechanical reperfusion for acute myocardial infarction. Am J 
Cardiol. 2001;88:170‐173, A6.
[19] Varani E, Balducelli M, Aquilina M, et al. Single or multivessel percutaneous coronary 
intervention in ST‐elevation myocardial infarction patients. Catheter Cardiovasc Interv. 
2008;72:927‐933.
[20] Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myo‐
cardial infarction. N Engl J Med. 2013;369:1115‐1123.
[21] Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion‐only 
revascularization in patients undergoing primary percutaneous coronary intervention 
for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015;65:963‐972.
[22] Engstrøm T, Kelbæk H, Helqvist S, et al. Complete re‐vascularisation versus treatment 
of the culprit lesion only in patients with ST‐segment elevation myocardial infarction 
and multivessel disease (DANAMI 3‐PRIMULTI): an open‐label, randomised controlled 
trial. Lancet. 2015;386:665‐671.
[23] Hlinomaz O. Multivessel coronary disease diagnosed at the time of primary PCI for 
STEMI: complete revascularization versus conservative strategy: the PRAGUE 13 trial. 
Paper presented at EuroPCR, 19‐22 May 2015, Paris, France.
[24] Cutlip DE, Windecker S, Mehran R, et al. Clinical endpoints in coronary stent trials: 
a case for standardized definitions. Circulation. 2007;115:2344‐2351.
[25] Gabriel S, Stefan K, James, DA, et al. The task force on the management of ST‐segment 
elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur 
Heart J. 2012. doi:10.1093/eurheartj/ehs215.
[26] Widimsky P, Holmes Jr David R. How to treat patients with ST‐elevation acute myocar‐
dial infarction and multi‐vessel disease? Eur Heart J. 2010. doi:10.1093/eurheartj/ehq410.
[27] Binder RK, Maier W, Luscher TF. Multi‐vessel revascularization in ST‐segment elevation 
myocardial infarction: where do we stand? Eur Heart J. 2016;37:217‐220. doi:10.1093/
eurheartj/ehv722.
[28] Goldstein JA, Demetriou D, Grines CL, et al. Multiple complex coronary plaques in 
patients with acute myocardial infarction. N Engl J Med. 2000;343:915‐922.
[29] Di Mario C, Mara S, Flavio A, et al. Single vs multivessel treatment during primary 
angioplasty: results of the multicenter randomised HEpacoat for culprit or multivessel 
stenting for Acute Myocardial Infarction (HELP AMI) study. Int J Cardiovasc Intervent. 
2004;6:128‐133.
Current Concept of Revascularization in STEMI Patients with Multivessel Coronary Artery Disease...
http://dx.doi.org/10.5772/67884
39
[30] Tarasov R, Ganyukov VI. Determination of optimal revascularization strategy in ST‐seg‐
ment elevation myocardial infarction patients with multivessel coronary disease with 
interactive calculator. Complex Issu Cardiovasc Dis. 2015;(4):42‐52 (in Russ.). doi:10.178
02/2306‐1278‐2015‐4‐42‐52.
[31] Garg S, Sarno G, Serruys РW, et al. Prediction of 1‐year clinical outcomes using the 
SYNTAX score in patients with acute ST‐segment elevation myocardial infarction 
undergoing primary percutaneous coronary intervention. J Am Coll Cardiol Intervent. 
2011;4(1):66‐67.
Interventional Cardiology40
